EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor‐Mediated Drug‐Induced Liver Injury Using a Liver‐On‐Chip Model

Alan Shi iD, Palak Agarwal iD, Zhang-Xu Liu iD, Paul M Beringer iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Alan Shi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elexacaftor/tezacaftor/ivacaftor (ETI), a cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, has provided great improvements in lung function and well‐being for people with CF. The use of ETI has been complicated by reports of rare but significant liver function test elevations in clinical trials and drug‐induced liver injury (DILI) in real‐world use. Previous research by our group revealed that oxidative stress is the major driver of ETI‐mediated DILI, and in silico ETI DILI simulations resulted in elevations of the emerging biomarker glutamine dehydrogenase (GLDH) which match the time course of predicted transaminase elevations. The assessment of emerging biomarkers and therapeutic strategies in a clinically relevant model will spur the development of more effective treatments for ETI‐mediated DILI. This study used the human‐relevant liver‐on‐chip model to investigate GLDH as a biomarker and ETI dose reduction and silymarin antioxidant administration as therapeutic strategies for ETI‐mediated DILI. We found that GLDH was not as sensitive as ALT and albumin for detecting DILI due to ETI. Dose reduction was a more effective treatment strategy for ETI DILI than silymarin, which did not significantly lower ALT levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryAminophenolsQuinolonesBenzodioxolesLiverLab-On-A-Chip DevicesIndolesPyridinesPyrazolesPyrrolidinesHumansDrug CombinationsBiomarkersOxidative StressLiver Function TestsCystic FibrosisCystic Fibrosis Transmembrane Conductance Regulator

Stichwörter der Autor:innen

CFTR modulatorDILIhepatotoxicityliver injuryliver‐on‐chip

Substanzen

AminophenolsQuinolonesBenzodioxolesDrug CombinationsBiomarkersIndolesivacaftorPyridinesCystic Fibrosis Transmembrane Conductance RegulatorPyrazoles

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
  • Translational Research Lab Core, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
  • USC Anton Yelchin CF Clinic, Los Angeles, California, USA.

ORCID-Profile: Alan Shi, Palak Agarwal, Zhang-Xu Liu, Paul M Beringer

Zitieren

APA

Shi, A., Agarwal, P., Liu, Z. X., & Beringer, P. M. (2025). Evaluation of Elexacaftor/Tezacaftor/Ivacaftor‐Mediated Drug‐Induced Liver Injury Using a Liver‐On‐Chip Model. Clinical and Translational Science. https://doi.org/10.1111/cts.70400

Vancouver

Shi A, Agarwal P, Liu ZX, Beringer PM. Evaluation of Elexacaftor/Tezacaftor/Ivacaftor‐Mediated Drug‐Induced Liver Injury Using a Liver‐On‐Chip Model. Clinical and Translational Science. 2025. doi:10.1111/cts.70400

BibTeX
@article{Shi2025,
  author = {Shi, Alan and Agarwal, Palak and Liu, Zhang-Xu and Beringer, Paul M},
  title = {Evaluation of Elexacaftor/Tezacaftor/Ivacaftor‐Mediated Drug‐Induced Liver Injury Using a Liver‐On‐Chip Model},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70400}
}
Kostenlos starten →